Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process - Abstract

Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC).

However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

Written by:
Seah JA, Blais N, North S, Rahim Y, Ruether D, Black PC, Zlotta AR, Wood L, Sridhar SS.   Are you the author?
Princess Margaret Hospital, Toronto, ON.

Reference: Can Urol Assoc J. 2013 Sep;7(9-10):312-8.
doi: 10.5489/cuaj.1506

PubMed Abstract
PMID: 24319508

UroToday.com Bladder Cancer Section